Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$0.55
-2.9%
$0.58
$0.16
$0.82
$592.41M0.251.23 million shs638,190 shs
InflaRx N.V. stock logo
IFRX
InflaRx
$0.90
+0.1%
$1.16
$0.71
$2.82
$60.08M1.29294,173 shs87,231 shs
Immunic, Inc. stock logo
IMUX
Immunic
$0.82
+1.8%
$0.85
$0.56
$2.11
$78.57M1.49976,857 shs396,515 shs
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$0.07
$0.01
$0.01
$726K1.632.58 million shs2.48 million shs
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$1.15
$1.06
$0.45
$1.68
$57.22M1.57.44 million shs15.01 million shs
The Next 7 Blockbuster Stocks for Growth Investors Cover

Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-2.56%-4.80%-15.91%+36.44%+221.69%
InflaRx N.V. stock logo
IFRX
InflaRx
+2.08%+10.25%+5.19%-0.66%-46.46%
Immunic, Inc. stock logo
IMUX
Immunic
-2.82%+13.02%-7.09%-8.85%-35.54%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00%0.00%0.00%0.00%0.00%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00%0.00%0.00%0.00%0.00%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.599 of 5 stars
0.03.00.00.03.10.80.0
InflaRx N.V. stock logo
IFRX
InflaRx
2.6832 of 5 stars
3.55.00.00.00.01.70.6
Immunic, Inc. stock logo
IMUX
Immunic
2.444 of 5 stars
3.61.00.00.02.02.50.6
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.00
N/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
3.00
Buy$6.60637.43% Upside
Immunic, Inc. stock logo
IMUX
Immunic
3.25
Buy$11.601,314.63% Upside
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
0.00
N/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest IFRX, INFI, ELTP, IMUX, and NEOS Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/25/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
6/5/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00
5/29/2025
InflaRx N.V. stock logo
IFRX
InflaRx
Raymond James Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Outperform$2.00
5/29/2025
InflaRx N.V. stock logo
IFRX
InflaRx
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetOutperform ➝ Outperform$6.00 ➝ $3.00
5/29/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$17.00 ➝ $10.00
5/23/2025
Immunic, Inc. stock logo
IMUX
Immunic
B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$6.00 ➝ $5.00
5/16/2025
Immunic, Inc. stock logo
IMUX
Immunic
William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
5/8/2025
InflaRx N.V. stock logo
IFRX
InflaRx
Oppenheimer
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOutperform$6.00
5/1/2025
Immunic, Inc. stock logo
IMUX
Immunic
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$10.00 ➝ $10.00
4/30/2025
Immunic, Inc. stock logo
IMUX
Immunic
D. Boral Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$17.00 ➝ $17.00
4/29/2025
InflaRx N.V. stock logo
IFRX
InflaRx
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageOverweight$10.00
(Data available from 7/10/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
$84.04M7.05$0.02 per share34.16$0.05 per share11.09
InflaRx N.V. stock logo
IFRX
InflaRx
$129.75K463.07N/AN/A$1.13 per share0.79
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/A$0.20 per shareN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
$2.59M0.00N/AN/A($0.21) per share0.00
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
$64.65M0.89N/AN/A($0.12) per share-9.58
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
-$4.32MN/A0.00N/A-5.13%3.96%2.13%8/14/2025 (Estimated)
InflaRx N.V. stock logo
IFRX
InflaRx
-$49.85M-$0.82N/AN/AN/AN/A-64.17%-53.39%8/6/2025 (Estimated)
Immunic, Inc. stock logo
IMUX
Immunic
-$100.51M-$1.23N/AN/AN/AN/A-326.95%-181.34%8/6/2025 (Estimated)
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
-$44.37M-$0.46N/AN/AN/A-1,593.93%N/A-113.02%N/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
-$16.90M-$0.34N/AN/AN/A-38.35%N/A-28.46%N/A

Latest IFRX, INFI, ELTP, IMUX, and NEOS Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
6/30/2025Q4 2025
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/A$0.01N/A$0.02N/A$32.00 million
5/15/2025Q1 2025
Immunic, Inc. stock logo
IMUX
Immunic
-$0.25-$0.25N/A-$0.25N/AN/A
5/7/2025Q1 2025
InflaRx N.V. stock logo
IFRX
InflaRx
-$0.18-$0.14+$0.04-$0.14$0.03 million$0.03 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
N/AN/AN/AN/AN/A
InflaRx N.V. stock logo
IFRX
InflaRx
N/AN/AN/AN/AN/A
Immunic, Inc. stock logo
IMUX
Immunic
N/AN/AN/AN/AN/A
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/AN/AN/AN/AN/A
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.08
4.88
3.50
InflaRx N.V. stock logo
IFRX
InflaRx
N/A
5.28
4.86
Immunic, Inc. stock logo
IMUX
Immunic
N/A
0.74
0.74
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
N/A
1.65
1.65
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
N/A
0.66
0.53

Institutional Ownership

CompanyInstitutional Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
0.01%
InflaRx N.V. stock logo
IFRX
InflaRx
42.39%
Immunic, Inc. stock logo
IMUX
Immunic
51.82%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
22.14%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
33.13%

Insider Ownership

CompanyInsider Ownership
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
14.42%
InflaRx N.V. stock logo
IFRX
InflaRx
16.30%
Immunic, Inc. stock logo
IMUX
Immunic
4.60%
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
9.81%
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
3.80%
CompanyEmployeesShares OutstandingFree FloatOptionable
Elite Pharmaceuticals Inc. stock logo
ELTP
Elite Pharmaceuticals
401.07 billion914.31 millionNot Optionable
InflaRx N.V. stock logo
IFRX
InflaRx
6067.13 million56.19 millionOptionable
Immunic, Inc. stock logo
IMUX
Immunic
7095.82 million91.41 millionOptionable
Infinity Pharmaceuticals, Inc. stock logo
INFI
Infinity Pharmaceuticals
3090.76 million81.86 millionOptionable
Neos Therapeutics, Inc. stock logo
NEOS
Neos Therapeutics
21349.76 millionN/AOptionable

Recent News About These Companies

MCET MultiCell Technologies, Inc.
NEOS/USD - NeosCoin US Dollar
Konstas and Harris to face Test grilling in Shield clash
Cara Therapeutics, Inc. (CARA)
Presidio Partners 2007 GP, L.P.'s Net Worth
Avenue Bank ready to tap into overlooked market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Elite Pharmaceuticals stock logo

Elite Pharmaceuticals OTCMKTS:ELTP

$0.55 -0.02 (-2.89%)
As of 12:20 PM Eastern

Elite Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals. It owns, licenses, manufactures, and sells various generic and oral dose pharmaceuticals products, such as Phentermine HCl 37.5mg tablets, and 15mg and 30mg capsules for the treatment of bariatrics under Adipex-P brand; Phendimetrazine Tartrate 35mg tablets for bariatrics under the Bontril brand; Naltrexone HCl 50mg tablets for the treatment of pains under the Revia brand; and Isradipine 2.5mg and 5mg capsules for cardiovascular diseases. The company also provides Trimipramine Maleate Immediate Release antidepressant capsules under the Surmontil brand; Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, and Amphetamine Sulfate Immediate Release tablets under the Adderall brand, as well as Dextroamphetamine Saccharate, Amphetamine Aspartate, Dextroamphetamine Sulfate, Amphetamine Sulfate Extended Release capsules under the Adderall XR brand for central nervous system diseases; Dantrolene Sodium capsules for muscle relaxant under the Dantrium brand; SequestOX, an immediate release Oxycodone with Naltrexone; Loxapine Succinate capsules for treating antipsychotic under the Loxapine brand; Acetaminophen and Codeine Phosphate for the management of mild to moderate pain; and antibiotic products. In addition, it manufactures controlled-release products on a contract basis for third parties in the areas of pain, allergy, bariatric, attention deficit, and infection. Further, the company is developing a range of abuse deterrent opioid products. Elite Pharmaceuticals, Inc. was incorporated in 1997 and is headquartered in Northvale, New Jersey.

InflaRx stock logo

InflaRx NASDAQ:IFRX

$0.90 +0.00 (+0.10%)
As of 12:31 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage. The company develops INF904, an oral, small molecule drug candidate for the chronic inflammatory and autoimmune diseases; IFX002 that is in pre-clinical development stage for the treatment of chronic inflammation and autoimmune diseases; and Gohibic (vilobelimab) for the treatment of COVID-19 and broader ARDS. It has co-development agreement with Beijing Defengrei Biotechnology Co. Ltd.; and clinical trial collaboration and supply agreement with Merck & Co. Inc. The company was formerly known as Fireman B.V. and changed its name to InflaRx N.V. in 2017. InflaRx N.V. was founded in 2007 and is headquartered in Jena, Germany.

Immunic stock logo

Immunic NASDAQ:IMUX

$0.82 +0.01 (+1.76%)
As of 12:35 PM Eastern
This is a fair market value price provided by Polygon.io. Learn more.

Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.

Infinity Pharmaceuticals stock logo

Infinity Pharmaceuticals NASDAQ:INFI

Infinity Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing novel medicines for people with cancer. The company's product candidate, including eganelisib (IPI-549), an orally administered clinical-stage immuno-oncology product candidate that inhibits the enzyme phosphoinositide-3-kinase-gamma, which is in Phase 2 clinical trials for the treatment of metastatic triple negative breast cancer and urothelial cancer; and Phase 1/1b clinical trials for the treatment of solid tumors. Infinity Pharmaceuticals, Inc. has strategic alliances with Intellikine, Inc. to discover, develop, and commercialize pharmaceutical products targeting the delta and/or gamma isoforms of PI3K; Verastem, Inc. to research, develop, commercialize, and manufacture duvelisib and products containing duvelisib; and PellePharm, Inc. to develop and commercialize rights to its hedgehog inhibitor program, IPI-926, a clinical-stage product candidate, as well as collaboration agreements with F. Hoffmann-La Roche Ltd., and Bristol Myers Squibb Company. Infinity Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Cambridge, Massachusetts.

Neos Therapeutics stock logo

Neos Therapeutics NASDAQ:NEOS

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.